These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 27058174

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Huntemann N, Rolfes L, Pawlitzki M, Ruck T, Pfeuffer S, Wiendl H, Meuth SG.
    Drugs; 2021 Jun; 81(9):1031-1063. PubMed ID: 34086251
    [Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H, Hohlfeld R.
    Neurology; 2009 Mar 17; 72(11):1008-15. PubMed ID: 19289741
    [Abstract] [Full Text] [Related]

  • 9. [An update on the treatment options for multiple sclerosis].
    Niino M.
    Brain Nerve; 2012 Dec 17; 64(12):1421-6. PubMed ID: 23209069
    [Abstract] [Full Text] [Related]

  • 10. Multiple sclerosis: clinical trial design 2019.
    Pardini M, Cutter G, Sormani MP.
    Curr Opin Neurol; 2019 Jun 17; 32(3):358-364. PubMed ID: 30950845
    [Abstract] [Full Text] [Related]

  • 11. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 17; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 12. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S, Eckstein C, Calabresi PA.
    Ann N Y Acad Sci; 2012 Jan 17; 1247():117-37. PubMed ID: 22224673
    [Abstract] [Full Text] [Related]

  • 13. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY, Constantinescu CS.
    Int J Clin Pract; 2010 Apr 17; 64(5):637-50. PubMed ID: 20456216
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G, Antonello RM, Zorzon M, Torre P, Zivadinov R, Moretti R, Bragadin LM, De Masi R, Nasuelli D.
    Recenti Prog Med; 1999 Oct 17; 90(10):538-44. PubMed ID: 10592740
    [Abstract] [Full Text] [Related]

  • 15. [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment].
    Wiendl H, Neuhaus O, Kappos L, Hohlfeld R.
    Nervenarzt; 2000 Aug 17; 71(8):597-610. PubMed ID: 10996910
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun 17; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 17. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X.
    J Neurol Sci; 2011 Dec 17; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [Abstract] [Full Text] [Related]

  • 18. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH.
    Curr Opin Neurol; 2003 Jun 17; 16(3):289-97. PubMed ID: 12858064
    [Abstract] [Full Text] [Related]

  • 19. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH, Naismith RT.
    J Intern Med; 2014 Apr 17; 275(4):350-63. PubMed ID: 24444048
    [Abstract] [Full Text] [Related]

  • 20. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE.
    West J Med; 1994 Sep 17; 161(3):292-8. PubMed ID: 7975569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.